PHP
AKYA

Parkman Healthcare Partners’s Akoya BioSciences AKYA Stock Holding History

Parkman Healthcare Partners’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-376,131
Closed -$1.02M – 91
2024
Q3 		$1.02M Buy
376,131
+595
+0.2% +$1.45K 0.13% 85
2024
Q2 		$879K Sell
375,536
-541,906
-59% -$1.73M 0.12% 81
2024
Q1 		$4.3M Buy
917,442
+242,655
+36% +$1.26M 0.53% 63
2023
Q4 		$3.29M Buy
674,787
+149,164
+28% +$620K 0.46% 65
2023
Q3 		$2.44M Buy
525,623
+54,623
+12% +$314K 0.45% 64
2023
Q2 		$3.48M Buy
471,000
+269,615
+134% +$1.8M 0.6% 54
2023
Q1 		$1.65M Buy
201,385
+60,130
+43% +$628K 0.36% 64
2022
Q4 		$1.35M Sell
141,255
-20,446
-13% -$252K 0.36% 66
2022
Q3 		$1.9M Sell
161,701
-23,084
-12% -$304K 0.54% 58
2022
Q2 		$2.37M Buy
184,785
+34,464
+23% +$357K 0.87% 39
2022
Q1 		$1.65M Buy
150,321
+25,321
+20% +$294K 0.48% 53
2021
Q4 		$1.91M Buy
+125,000
New +$1.64M 0.42% 61

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PCA
Peddock Capital Advisors Braintree, Massachusetts $501M AUM 29.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Parkman Healthcare Partners's AKYA Position: Q4 2024 in Review

Parkman Healthcare Partners sold out of Akoya BioSciences (AKYA) in Q4 2024, closing a stake of 376,131 shares — an estimated $1.02M sold.

Parkman Healthcare Partners first reported a position in AKYA in Q4 2021 and held it in 12 quarters. The position peaked at $4.3M in Q1 2024. 61 funds tracked by Wall St. Rank hold AKYA as of Q4 2024.

  • Parkman Healthcare Partners reported no remaining Akoya BioSciences position as of Q4 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 376,131 Akoya BioSciences shares in Q4 2024, an estimated $1.02M.
  • Parkman Healthcare Partners first reported a position in Akoya BioSciences in Q4 2021 and held it in 12 quarters.
  • Parkman Healthcare Partners's Akoya BioSciences position peaked at $4.3M in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Akoya BioSciences as of Q4 2024.

Based on Parkman Healthcare Partners's 13F filing for Q4 2024, filed 14 Feb 2025.